Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 12

Results For "CDSCO"

157 News Found

Cipla gets approval from SEC to conduct Paxlovid trials
News | March 03, 2022

Cipla gets approval from SEC to conduct Paxlovid trials

Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations


India grants Emergency Use Authorisation to Sputnik Light
News | February 07, 2022

India grants Emergency Use Authorisation to Sputnik Light

This is the ninth Covid-19 vaccine approved in India


Expert panel recommends Emergency Use Authorisation for Sputnik Light
News | February 05, 2022

Expert panel recommends Emergency Use Authorisation for Sputnik Light

The recommendations have been sent to the Drugs Controller General of India (DCGI) for the final approval


DCGI approves Bharat Biotech’s Phase 3 trials for intranasal vaccine
News | January 29, 2022

DCGI approves Bharat Biotech’s Phase 3 trials for intranasal vaccine

Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission


Covaxin and Covishield granted conditional market approval
News | January 27, 2022

Covaxin and Covishield granted conditional market approval

The vaccines are currently only authorised for emergency use in the country


SEC recommends regular market approval for Covishield and Covaxin
News | January 20, 2022

SEC recommends regular market approval for Covishield and Covaxin

However, these won’t be available at the nearest chemist store soon


Molnupiravir best option to treat Covid-19 now: Experts
News | January 11, 2022

Molnupiravir best option to treat Covid-19 now: Experts

Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients


Aurobindo Pharma rolls out Molnaflu in India
News | January 06, 2022

Aurobindo Pharma rolls out Molnaflu in India

The brand is now available pan-India through their distribution partner


Study demonstrates Covaxin safe for kids in the age 2-18 years
News | December 30, 2021

Study demonstrates Covaxin safe for kids in the age 2-18 years

Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults


JB Chemicals and Pharmaceuticals to launch molnupiravir next month
Drug Approval | December 29, 2021

JB Chemicals and Pharmaceuticals to launch molnupiravir next month

It will be marketed under the brand name Molunamax